SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/20.09.24 Stock SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/20.09.24
Add to a list
To use this feature you must be a member
Log inSign up

SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/20.09.24 Stock

Warrant

DE000SV6QT30

Market Closed - Deutsche Boerse AG 03:45:50 2024-06-14 pm EDT
1.77 EUR +0.57% Intraday chart for SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/20.09.24
Current month-1.12%
1 month+24.65%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors BU
More news

Quotes 5-day view

Date Price Change
24-06-14 1.77 +0.57%
24-06-13 1.76 +7.32%
24-06-12 1.64 +1.23%
24-06-11 1.62 -2.41%
24-06-10 1.66 -5.14%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 03:45 pm EDT

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying BRISTOL-MYERS SQUIBB COMPANY
IssuerLogo Issuer Société Générale Société Générale
WKN SV6QT3
ISINDE000SV6QT30
Date issued 2023-05-24
Strike 60 $
Maturity 2024-09-20 (97 Days)
Parity 10 : 1
Emission price 0.41 €
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 1.85 €
Lowest since issue 0.31 €
Delta-0.88x
Omega 1.897
Premium1.01x
Gearing2.14x
Moneyness 1.456
Difference Strike 18.8 $
Difference Strike %+31.33%
Spread 0.01 €
Spread %0.56%
Intrinsic value 1.756

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2 USD
Average target price
53.19 USD
Spread / Average Target
+29.11%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant